Search Results - "Platt, James T"

β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas by Damsky, William E., Curley, David P., Santhanakrishnan, Manjula, Rosenbaum, Lara E., Platt, James T., Gould Rothberg, Bonnie E., Taketo, Makoto M., Dankort, David, Rimm, David L., McMahon, Martin, Bosenberg, Marcus

“…Malignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this process have not been clearly delineated. Although it…”
Get full text

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening by Held, Matthew A, Langdon, Casey G, Platt, James T, Graham-Steed, Tisheeka, Liu, Zongzhi, Chakraborty, Ashok, Bacchiocchi, Antonella, Koo, Andrew, Haskins, Jonathan W, Bosenberg, Marcus W, Stern, David F

“…Resistance and partial responses to targeted monotherapy are major obstacles in cancer treatment. Systematic approaches to identify efficacious drug…”
Get more information

PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets by Scortegagna, Marzia, Lau, Eric, Zhang, Tongwu, Feng, Yongmei, Sereduk, Chris, Yin, Hongwei, De, Surya K, Meeth, Katrina, Platt, James T, Langdon, Casey G, Halaban, Ruth, Pellecchia, Maurizio, Davies, Michael A, Brown, Kevin, Stern, David F, Bosenberg, Marcus, Ronai, Ze'ev A

“…Melanoma development involves members of the AGC kinase family, including AKT, PKC, and, most recently, PDK1, as elucidated recently in studies of Braf::Pten…”
Get full text

MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL by Tworkoski, Kathryn A., Platt, James T., Bacchiocchi, Antonella, Bosenberg, Marcus, Boggon, Titus J., Stern, David F.

“…Summary The receptor tyrosine kinase AXL regulates melanoma cell proliferation and migration. We now demonstrate that AXL and the related kinase MERTK are…”
Get full text

Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells by Wali, Vikram B, Haskins, Jonathan W, Gilmore-Hebert, Maureen, Platt, James T, Liu, Zongzhi, Stern, David F

“…Associations of ErbB4 (ERBB4/HER4), the fourth member of the EGFR family, with cancer are variable, possibly as a result of structural diversity of this…”
Get full text

mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation by Damsky, William, Micevic, Goran, Meeth, Katrina, Muthusamy, Viswanathan, Curley, David P., Santhanakrishnan, Manjula, Erdelyi, Ildiko, Platt, James T., Huang, Laura, Theodosakis, Nicholas, Zaidi, M. Raza, Tighe, Scott, Davies, Michael A., Dankort, David, McMahon, Martin, Merlino, Glenn, Bardeesy, Nabeel, Bosenberg, Marcus

“…BrafV600E induces benign, growth-arrested melanocytic nevus development, but also drives melanoma formation. Cdkn2a loss in BrafV600E melanocytes in mice…”
Get full text

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma by McFadden, David G., Politi, Katerina, Bhutkar, Arjun, Chen, Frances K., Song, Xiaoling, Pirun, Mono, Santiago, Philip M., Kim-Kiselak, Caroline, Platt, James T., Lee, Emily, Hodges, Emily, Rosebrock, Adam P., Bronson, Roderick T., Socci, Nicholas D., Hannon, Gregory J., Jacks, Tyler, Varmus, Harold

“…Genetically engineered mouse models (GEMMs) of cancer are increasingly being used to assess putative driver mutations identified by large-scale sequencing of…”
Get full text

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer by Wali, Vikram B, Langdon, Casey G, Held, Matthew A, Platt, James T, Patwardhan, Gauri A, Safonov, Anton, Aktas, Bilge, Pusztai, Lajos, Stern, David F, Hatzis, Christos

“…Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing…”
Get full text

Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer by Colavito, Sierra A, Platt, James T, Held, Matthew A, Liu, Zongzhi, Sokup, Ryan, Stern, David F

“…Mesenchymal stem-like (MSL) breast cancers are enriched for cells with tumor reconstituting and mesenchymal characteristics. These cancers are often…”
Get full text

Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor by Langdon, Casey G, Platt, James T, Means, Robert E, Iyidogan, Pinar, Mamillapalli, Ramanaiah, Klein, Michael, Held, Matthew A, Lee, Jong Woo, Koo, Ja Seok, Hatzis, Christos, Hochster, Howard S, Stern, David F

“…Pancreatic adenocarcinoma (PDAC) is the fourth most common cause of cancer-related death in the United States. PDAC is difficult to manage effectively, with a…”
Get full text

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells by Langdon, Casey G, Wiedemann, Norbert, Held, Matthew A, Mamillapalli, Ramanaiah, Iyidogan, Pinar, Theodosakis, Nicholas, Platt, James T, Levy, Frederic, Vuagniaux, Gregoire, Wang, Shaomeng, Bosenberg, Marcus W, Stern, David F

“…Targeting anti-apoptotic proteins can sensitize tumor cells to conventional chemotherapies or other targeted agents. Antagonizing the Inhibitor of Apoptosis…”
Get full text

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors by Langdon, Casey G., Held, Matthew A., Platt, James T., Meeth, Katrina, Iyidogan, Pinar, Mamillapalli, Ramanaiah, Koo, Andrew B., Klein, Michael, Liu, Zongzhi, Bosenberg, Marcus W., Stern, David F.

“…Summary BRAF inhibitors have revolutionized treatment of mutant BRAF metastatic melanomas. However, resistance develops rapidly following BRAF inhibitor…”
Get full text

mTORC1 Activation Blocks Braf V600E -Induced Growth Arrest but Is Insufficient for Melanoma Formation by Damsky, William, Micevic, Goran, Meeth, Katrina, Muthusamy, Viswanathan, Curley, David P, Santhanakrishnan, Manjula, Erdelyi, Ildiko, Platt, James T, Huang, Laura, Theodosakis, Nicholas, Zaidi, MRaza, Tighe, Scott, Davies, Michael A, Dankort, David, McMahon, Martin, Merlino, Glenn, Bardeesy, Nabeel, Bosenberg, Marcus

“…Braf V600E induces benign, growth-arrested melanocytic nevus development, but also drives melanoma formation. Cdkn2a loss in Braf V600E melanocytes in mice…”
Get full text

Salmonella pathogenicity island-2 and anticancer activity in mice by Pawelek, John M, Sodi, Stefano, Chakraborty, Ashok K, Platt, James T, Miller, Samuel, Holden, David W, Hensel, Michael, Low, K Brooks

“…Salmonella enterica servovar Typhimurium is capable of targeting, colonizing, and eliciting growth suppression of tumors in mice. We examined the effects of…”
Get full text

Polymerization of 5,6‐Dihydroxyindole‐2‐Carboxylic Acid to Melanin by the Pmel 17/Silver Locus Protein by Chakraborty, Ashok K., Platt, James T., Kim, Kack K., Kwon, Byoung, Bennett, Dorothy C., Pawelek, John M.

“…Recent advances in melanogenesis have focused on the role of dihydroxyindole‐2‐carboxylic acid [(HO)2IndCOOH]. For example, it has been shown that formation of…”
Get full text

Abstract 1792: Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer by Langdon, Casey G., Wiedemann, Norbert, Hajjami, Hélène Maby-El, Held, Mathew A., Platt, James T., Vuagniaux, Grégoire, Bosenberg, Marcus W., Stern, David F., Lévy, Frédéric

“…Abstract Background: Drug resistance is a major problem in cancer therapy, which can be addressed by simultaneously targeting multiple critical nodes of the…”
Get full text

Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma by Langdon, Casey G., Wiedemann, Norbert, Held, Matthew A., Platt, James T., Mamillapalli, Ramanaiah, Iyidogan, Pinar, Theodosakis, Nicholas, Levy, Frederic, Robichon, Denis, Zanna, Claudio, Vuagniaux, Gregoire, Sorensen, Mel, Wang, Shaomeng, Bosenberg, Marcus W., Stern, David F.

“…Abstract Efficient induction of cell death is essential for efficacy of cancer therapies, and may be enhanced in combination therapies that promote apoptosis…”
Get full text

Abstract B275: Dovitinib as a single-agent or in combination with other small molecule inhibitors for mutant BRAF melanomas by Langdon, Casey G., Held, Matthew A., Koo, Andrew B., Klein, Michael, Liu, Zongzhi, Platt, James T., Stern, David F.

“…Abstract Background: Receptor tyrosine kinases (RTKs) modulate many oncogenic signaling pathways. RTKs can be activated as a result of feedback loops initiated…”
Get full text

Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models by Langdon, Casey G., Wiedemann, Norbert, Held, Mathew A., Platt, James T., Lévy, Frédéric, Robichon, Denis, Zanna, Claudio, Vuagniaux, Grégoire, Sorensen, Mel, Wang, Shaomeng, Bosenberg, Marcus W., Stern, David F.

“…Abstract Background: Drug resistance is a major problem in cancer therapy that may be addressed by the combination of drugs simultaneously targeting multiple…”
Get full text

Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells by Langdon, Casey G., Wiedemann, Norbert, Held, Mathew A., Platt, James T., Lévy, Frédéric, Zanna, Claudio, Vuagniaux, Grégoire, Sorensen, Mel, Wang, Shaomeng, Bosenberg, Marcus W., Stern, David F.

“…Abstract Background: Drug resistance is a major problem in cancer therapy. The combination of drugs targeting simultaneously multiple critical nodes of the…”
Get full text